Click to copy

Press release content from BusinessWire. The AP news staff was not involved in its creation.

Click to copy

Global Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor Pipeline Report 2018 - ResearchAndMarkets.com

December 20, 2018

DUBLIN--(BUSINESS WIRE)--Dec 20, 2018--The “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Tiziana Life Sciences plc MetaMax Tragara Pharmaceuticals Merck Sharp & Dohme Corp. Bayer HealthCare Pharmaceuticals Piramal Enterprises Merck Onconova Therapeutics Presage Biosciences Jiangsu HengRui Medicine Roche Pharm

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l5rq4t/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005819/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900